Skip to main content

February 2024

Recruitment for M.Pharm, B.Pharm, M.Sc in Multiple Departments at SunGlow Life Science

SunGlow was incorporated in January 2010 and was founded by a group of experienced industry professionals. Our Corporate office is located in Chennai, India. The first facility located in Puducherry, a small state in the southern part of India, about 145 kilometres south of Chennai manufactures for the domestic market. The second facility is located in Chengalpattu, a town about 80 kilometres southwest of Chennai manufactures for the global market.

Walk in drive for Medical Representative at Lupin Limited

Lupin Limited is one of India's largest manufacturers of bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.

Post : Medical Representative

Torrent Pharma hiring Product Executive / Assistant Product Manager

Torrent Pharma, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.

Walk in Drive for M.Pharm, B.Pharm, M.Sc in QA, QC at Felix Generics

A pharmaceutical generics business company. HPRA Approved (April 2021) facility for veterinary generic medicines. Parent entity based in Ireland. Indian corporate office located at Gurgaon and R&D Center is at Greater Noida. Manufacturing facility based at SEZ Pithampur, Indore.

JAMP group Inviting proficient Pharmacovigilance experts

The JAMP group is a proud Canadian owned company with its international headquarters located in Boucherville, 20 minutes from downtown Montreal, Quebec, Canada. The JAMP Pharma Group is active in all sectors of the pharmaceutical industry with our JAMP Pharma Generics, Orimed branded products, our Wampole and Laboratoire Suisse natural health supplements and our Cosmetic Import beauty and personal care products. The JAMP Pharma Group has also made a major investment in biosimilars which is one of the fastest growing markets in the pharmaceutical industry.

Interview for B.Pharm, M.Pharm in QA, QC, Regulatory Affairs, F&D at Bharat Parenterals

Bharat Parenterals Ltd. is a Gujarat based pharmaceutical company, established in 1992 by Mr. Ramesh Desai, who started the company with a vision of making world class affordable medicines and to take it to the forefront of contract manufacturing units in Gujarat.

Work as Research Assistant at Universiti Malaya, MSc, B.Pharm Apply

Universiti Malaya, or UM, Malaysia's oldest university, is situated on a 922 acre (373.12 hectare) campus in the southwest of Kuala Lumpur, the capital of Malaysia.  It was founded on 28 September 1905 in Singapore as the King Edward VII College of Medicine and  on 8th October 1949, it became the Universiti Malaya with  the merger of the King Edward VII College of Medicine and Raffles College (founded in 1928).

Post : Graduate Research Assistant

NIHR awards 7m Euro to the University of Birmingham to provide strategic leadership for its Research Support Service

The NIHR has selected the University of Birmingham to run the National Collaborative for its Research Support Service (RSS) from 1 February 2024.

The RSS was launched on 1 October 2023. The service provides expert research design, methodological support, advice, and collaboration to all researchers in England throughout the pre- and post-application/research process, regardless of geographic location and research interest.

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

BioNTech SE a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations. In connection with the strategic collaboration, the companies entered into a license and option agreement and a securities purchase agreement.

Bristol Myers Squibb announces acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy

Bristol Myers Squibb announced two regulatory acceptances for applications for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics Application (sBLA) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 8, 2024.